Marc Serota, MD

Marc Serota, MD, discussed upcoming systemic JAK inhibitors, the value of ruxolitinib cream and phototherapy, and a personalized multimodal approach to improve repigmentation outcomes.

Marc Serota, MD, notes that areas lacking hair follicles respond more slowly to therapy and benefit from long-term, low-risk use of topical ruxolitinib.

Marc Serota, MD, outlines how ruxolitinib cream supports gradual, sustained repigmentation, highlights the significance of “islands” of early pigment return, and discusses when to escalate or combine modalities to optimize outcomes.

Marc Serota, MD, discusses using ruxolitinib cream to safely maintain repigmentation, minimize steroid-related adverse effects, and enhance outcomes when combined with phototherapy.

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.